Top

Current Neurology and Neuroscience Reports

Published in:

Open Access 16-12-2023 | Multiple Sclerosis | Review

Hormonal Therapies in Multiple Sclerosis: a Review of Clinical Data

Authors: Stephanie Hsu, Riley Bove

Published in: Current Neurology and Neuroscience Reports | Issue 1/2024

Abstract

Purpose of Review

Given the potential for exogenous hormones to influence risk and course of MS, this narrative review aims to summarize current knowledge from observational and interventional studies of exogenous hormones in humans with MS.

Recent Findings

Large randomized clinical trials for combined oral contraceptives and estriol both show modest effect on inflammatory activity, with the latter showing potential neuroprotective effect. After fertility treatment, large actively treated cohorts have not confirmed any elevated risk of relapse. Preclinical data suggest that androgens, selective estrogen receptor modulators (SERMs), and selective androgen receptor modulators (SARMs) may be neuroprotective but clinical data are lacking. Gender affirming treatment, particularly estrogen in trans-women, could possibly be associated with elevated risk of inflammation. For women with MS entering menopause, hormone therapy appears safe during the appropriate menopausal window, but its long-term effects on neuroprotection are unknown.

Summary

Exogenous hormones, used in varied doses and for diverse indications, have variable effects on MS risk, inflammatory activity, and neuroprotection. Large randomized trials are needed before it is possible to determine the true effect of exogenous hormones in a condition as complex as MS.

Ysrraelit MC, Correale J. Impact of sex hormones on immune function and multiple sclerosis development. Immunology. 2019;156(1):9–22. https://doi.org/10.1111/imm.13004.CrossRefPubMed

Colquitt CW, Martin TS. Contraceptive methods. J Pharm Pract. 2017;30(1):130–5. https://doi.org/10.1177/0897190015585751.CrossRefPubMed

Huck LC, Truhn D, Wilpert C, Zanderigo E, Raaff V, Dethlefsen E, et al. Background parenchymal enhancement in contrast-enhanced MR imaging suggests systemic effects of intrauterine contraceptive devices. Eur Radiol. 2022;32(11):7430–8. https://doi.org/10.1007/s00330-022-08809-0.CrossRefPubMedPubMedCentral

Depypere HT, Stanczyk FZ, Croubels S, Blondeel PN, Roche NA, Depypere BP, et al. Breast levonorgestrel concentrations in women using a levonorgestrel-releasing intrauterine system. Contraception. 2019;100(4):299–301. https://doi.org/10.1016/j.contraception.2019.07.002.CrossRefPubMed

Bove R, Rankin K, Chua AS, Saraceno T, Sattarnezhad N, Greeke E, et al. Oral contraceptives and MS disease activity in a contemporary real-world cohort. Mult Scler. 2018;24(2):227–30. https://doi.org/10.1177/1352458517692420.CrossRefPubMed

• Otero-Romero S, Carbonell-Mirabent P, Midaglia L, Zuluaga M, Galán I, Cobo-Calvo A, et al. Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. Mult Scler. 2022;28(6):950–7. https://doi.org/10.1177/13524585211053001. (In this observational study, exposure to OC use in women with CIS was found to not be associated with the risk of either a second attack or of disability accrual, suggesting overall little effect of combined OCs on risk of inflammatory activity,)CrossRefPubMed

Chen CS, Krishnakumar T, Rowles W, Anderson A, Zhao C, Do L, et al. Comparison of MS inflammatory activity in women using continuous versus cyclic combined oral contraceptives. Multiple sclerosis and related disorders. 2020;41: 101970. https://doi.org/10.1016/j.msard.2020.101970.CrossRefPubMed

Pozzilli C, De Giglio L, Barletta VT, Marinelli F, Angelis FD, Gallo V, et al. Oral contraceptives combined with interferon beta in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2015;2(4): e120. https://doi.org/10.1212/NXI.0000000000000120.CrossRefPubMedPubMedCentral

• Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. The Lancet Neurology. 2016;15(1):35–46. https://doi.org/10.1016/S1474-4422(15)00322-1. (This interventional study found that treatment with estriol, along with glatiramer acetate, in women with RRMS, was well-tolerated and reduced relapse rates.)CrossRefPubMed

10.

Disanto G, Barro C, Benkert P, Naegelin Y, Schadelin S, Giardiello A, et al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857–70. https://doi.org/10.1002/ana.24954.CrossRefPubMedPubMedCentral

11.

Voskuhl R, Kuhle J, Siddarth P, Itoh N, Patel K, MacKenzie-Graham A. Decreased neurofilament light chain levels in estriol-treated multiple sclerosis. Ann Clin Transl Neurol. 2022;9(8):1316–20. https://doi.org/10.1002/acn3.51622.CrossRefPubMedPubMedCentral

12.

Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med. 1998;339(5):285–91. https://doi.org/10.1056/NEJM199807303390501.CrossRefPubMed

13.

Anderson A, Krysko KM, Rutatangwa A, Krishnakumar T, Chen C, Rowles W, et al. Clinical and radiologic disease activity in pregnancy and postpartum in MS. Neurol Neuroimmunol Neuroinflamm. 2021;8(2):e959. https://doi.org/10.1212/NXI.0000000000000959.CrossRefPubMedPubMedCentral

14.

Vukusic S, Ionescu I, El-Etr M, Schumacher M, Baulieu EE, Cornu C, et al. The Prevention of post-partum relapses with progestin and estradiol in multiple sclerosis (POPART’MUS) trial: rationale, objectives and state of advancement. J Neurol Sci. 2009;286(1–2):114–8. https://doi.org/10.1016/j.jns.2009.08.056.CrossRefPubMed

15.

Vukusic S, Ionescu I, Cornu C, Bossard N, Durand-Dubief F, Cotton F, et al. Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: the POPARTMUS study. Mult Scler. 2021;27(9):1458–63. https://doi.org/10.1177/1352458520978218.CrossRefPubMed

16.

Taylor H, Alhasan S, Saleem M, Poole S, Jiang F, Longbrake EE, Bove R. Influence of menstrual cycle and hormonal contraceptive use on MS symptom fluctuations: a pilot study. Mult Scler Relat Disord. 2023;77:104864. https://doi.org/10.1016/j.msard.2023.1048.

17.

Bove R, Healy BC, Musallam A, Glanz BI, De Jager PL, Chitnis T. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler. 2016;22(7):935–43. https://doi.org/10.1177/1352458515606211.CrossRefPubMed

18.

Bove R, Vaughan T, Chitnis T, Wicks P, De Jager PL. Women’s experiences of menopause in an online MS cohort: a case series. Mult Scler Relat Disord. 2016;9:56–9. https://doi.org/10.1016/j.msard.2016.06.015.CrossRefPubMedPubMedCentral

19.

Zeydan B, Atkinson EJ, Weis DM, Smith CY, Gazzuola Rocca L, Rocca WA, et al. Reproductive history and progressive multiple sclerosis risk in women. Brain Commun. 2020;2(2):fcaa185. https://doi.org/10.1093/braincomms/fcaa185.CrossRefPubMedPubMedCentral

20.

Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159–68. https://doi.org/10.1210/jc.2011-3362.CrossRefPubMedPubMedCentral

21.

The 2022 hormone therapy position statement of The North American Menopause Society. Menopause (New York, NY). 2022;29(7):767–94. https://doi.org/10.1097/gme.0000000000002028.

22.

Morales-Rodriguez D, Anderson A, Nylander A, Hsu S, Singh J, Rowles W, et al. Well-being at midlife: correlates of mental health in ambulatory menopausal women with multiple sclerosis. Mult Scler. 2023;29(11–12):1493–502. https://doi.org/10.1177/13524585231197056.CrossRefPubMedPubMedCentral

23.

Joffe H, Guthrie KA, LaCroix AZ, Reed SD, Ensrud KE, Manson JE, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med. 2014;174(7):1058–66. https://doi.org/10.1001/jamainternmed.2014.1891.CrossRefPubMedPubMedCentral

24.

Depypere H, Lademacher C, Siddiqui E, Fraser GL. Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs. 2021;30(7):681–94. https://doi.org/10.1080/13543784.2021.1893305.CrossRefPubMed

25.

Menown SJ, Tello JA. Neurokinin 3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes: a systematic qualitative review. Adv Ther. 2021;38(10):5025–45. https://doi.org/10.1007/s12325-021-01900-w.CrossRefPubMedPubMedCentral

26.

D’Hoore L, T’Sjoen G. Gender-affirming hormone therapy: an updated literature review with an eye on the future. J Intern Med. 2022;291(5):574–92. https://doi.org/10.1111/joim.13441.CrossRefPubMed

27.

• Bove R, Anderson A, Rowles W, Rankin KA, Hills NK, Carleton M, et al. A hormonal therapy for menopausal women with MS: a phase Ib/IIa randomized controlled trial. Multiple sclerosis and related disorders. 2022;61: 103747. https://doi.org/10.1016/j.msard.2022.103747. (This study was a small interventional trial evaluating the role of menopausal hormone therapy on vasomotor symptoms in women with MS.)

28.

Juutinen L, Ahinko K, Tinkanen H, Rosti-Otajärvi E, Sumelahti ML. Menopausal symptoms and hormone therapy in women with multiple sclerosis: a baseline-controlled study. Multiple sclerosis and related disorders. 2022;67: 104098. https://doi.org/10.1016/j.msard.2022.104098.CrossRefPubMed

29.

Freeman EW, Ensrud KE, Larson JC, Guthrie KA, Carpenter JS, Joffe H, et al. Placebo improvement in pharmacologic treatment of menopausal hot flashes: time course, duration, and predictors. Psychosom Med. 2015;77(2):167–75. https://doi.org/10.1097/PSY.0000000000000143.CrossRefPubMedPubMedCentral

30.

Baroncini D, Annovazzi PO, De Rossi N, Mallucci G, Torri Clerici V, Tonietti S, et al. Impact of natural menopause on multiple sclerosis: a multicentre study. J Neurol Neurosurg Psychiatry. 2019;90(11):1201–6. https://doi.org/10.1136/jnnp-2019-320587.CrossRefPubMed

31.

Ladeira F, Salavisa M, Caetano A, Barbosa R, Sá F, Correia AS. The influence of menopause in multiple sclerosis course: a longitudinal cohort study. Eur Neurol. 2018;80(3–4):223–7. https://doi.org/10.1159/000496374.CrossRefPubMed

32.

Otero-Romero S, Midaglia L, Carbonell-Mirabent P, Zuluaga M, Galán I, Río J, et al. Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset. Eur J Neurol. 2022;29(4):1075–81. https://doi.org/10.1111/ene.14782.CrossRefPubMed

33.

Kopp TI, Lidegaard Ø, Magyari M. Hormone therapy and disease activity in Danish women with multiple sclerosis: a population-based cohort study. Eur J Neurol. 2022;29(6):1753–62. https://doi.org/10.1111/ene.15299.CrossRefPubMedPubMedCentral

34.

Bove R, Healy BC, Secor E, Vaughan T, Katic B, Chitnis T, et al. Patients report worse MS symptoms after menopause: findings from an online cohort. Multiple Sclerosis Relat Disorders. 2015;4(1):18–24. https://doi.org/10.1016/j.msard.2014.11.009.CrossRef

35.

Guo H, Liu M, Zhang L, Wang L, Hou W, Ma Y, et al. the critical period for neuroprotection by estrogen replacement therapy and the potential underlying mechanisms. Curr Neuropharmacol. 2020;18(6):485–500. https://doi.org/10.2174/1570159X18666200123165652.CrossRefPubMedPubMedCentral

36.

Bove R, Secor E, Chibnik LB, Barnes LL, Schneider JA, Bennett DA, et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology. 2014;82(3):222–9. https://doi.org/10.1212/WNL.0000000000000033.CrossRefPubMedPubMedCentral

37.

• Coughlan GT, Betthauser TJ, Boyle R, Koscik RL, Klinger HM, Chibnik LB, et al. Association of age at menopause and hormone therapy use with tau and β-amyloid positron emission tomography. JAMA Neurol. 2023;80(5):462–73. https://doi.org/10.1001/jamaneurol.2023.0455. (This study found higher tau deposition in cognitively unimpaired females compared to age-matched cognitively unimpaired males, and more specifically, found that earlier age at menopause and later initiation of hormone therapy increased tau levels.)

38.

Lord C, Buss C, Lupien SJ, Pruessner JC. Hippocampal volumes are larger in postmenopausal women using estrogen therapy compared to past users, never users and men: a possible window of opportunity effect. Neurobiol Aging. 2008;29(1):95–101. https://doi.org/10.1016/j.neurobiolaging.2006.09.001.CrossRefPubMed

39.

Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA. 2004;291(24):2947–58. https://doi.org/10.1001/jama.291.24.2947.CrossRefPubMed

40.

Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, LeBlanc ES, et al. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med. 2013;173(15):1429–36. https://doi.org/10.1001/jamainternmed.2013.7727.CrossRefPubMed

41.

Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-cognitive and affective study. PLoS Med. 2015;12(6):e1001833. https://doi.org/10.1371/journal.pmed.1001833. (discussion e).CrossRefPubMedPubMedCentral

42.

Jover T, Tanaka H, Calderone A, Oguro K, Bennett MV, Etgen AM, et al. Estrogen protects against global ischemia-induced neuronal death and prevents activation of apoptotic signaling cascades in the hippocampal CA1. J Neurosci. 2002;22(6):2115–24. https://doi.org/10.1523/JNEUROSCI.22-06-02115.2002.CrossRefPubMedPubMedCentral

43.

Roehm E. A reappraisal of women’s health initiative estrogen-alone trial: long-term outcomes in women 50–59 years of age. Obstet Gynecol Int. 2015;2015: 713295. https://doi.org/10.1155/2015/713295.CrossRefPubMedPubMedCentral

44.

Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221–31. https://doi.org/10.1056/NEJMoa1505241.CrossRefPubMedPubMedCentral

45.

Sherwin BB. Estrogen therapy: is time of initiation critical for neuroprotection? Nat Rev Endocrinol. 2009;5(11):620–7. https://doi.org/10.1038/nrendo.2009.193.CrossRefPubMed

46.

Henderson VW, St John JA, Hodis HN, McCleary CA, Stanczyk FZ, Shoupe D, et al. Cognitive effects of estradiol after menopause: a randomized trial of the timing hypothesis. Neurology. 2016;87(7):699–708. https://doi.org/10.1212/WNL.0000000000002980.CrossRefPubMedPubMedCentral

47.

• Bove R, White CC, Fitzgerald KC, Chitnis T, Chibnik L, Ascherio A, et al. Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis. Neurology. 2016;87(14):1457–63. https://doi.org/10.1212/WNL.0000000000003176. (This observational study found that systemic hormone therapy use was associated with better physical quality of life in postmenopausal women with MS.)CrossRefPubMedPubMedCentral

48.

Foster SC, Daniels C, Bourdette DN, Bebo BF Jr. Dysregulation of the hypothalamic-pituitary-gonadal axis in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neuroimmunol. 2003;140(1–2):78–87. https://doi.org/10.1016/s0165-5728(03)00177-2.CrossRefPubMed

49.

Tomassini V, Onesti E, Mainero C, Giugni E, Paolillo A, Salvetti M, et al. Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J Neurol Neurosurg Psychiatry. 2005;76(2):272–5. https://doi.org/10.1136/jnnp.2003.033324.CrossRefPubMedPubMedCentral

50.

Bove R, Musallam A, Healy BC, Raghavan K, Glanz BI, Bakshi R, et al. Low testosterone is associated with disability in men with multiple sclerosis. Mult Scler. 2014;20(12):1584–92. https://doi.org/10.1177/1352458514527864.CrossRefPubMedPubMedCentral

51.

Whitacre CC, Reingold SC, O’Looney PA. A gender gap in autoimmunity. Science. 1999;283(5406):1277–8. https://doi.org/10.1126/science.283.5406.1277.CrossRefPubMed

52.

Gold SM, Voskuhl RR. Estrogen and testosterone therapies in multiple sclerosis. Prog Brain Res. 2009;175:239–51. https://doi.org/10.1016/S0079-6123(09)17516-7.CrossRefPubMedPubMedCentral

53.

Gubbels Bupp MR, Jorgensen TN. Androgen-induced Immunosuppression. Front Immunol. 2018;9:794. https://doi.org/10.3389/fimmu.2018.00794.CrossRefPubMedPubMedCentral

54.

Sicotte NL, Giesser BS, Tandon V, Klutch R, Steiner B, Drain AE, et al. Testosterone treatment in multiple sclerosis: a pilot study. Arch Neurol. 2007;64(5):683–8. https://doi.org/10.1001/archneur.64.5.683.CrossRefPubMed

55.

Kurth F, Luders E, Sicotte NL, Gaser C, Giesser BS, Swerdloff RS, et al. Neuroprotective effects of testosterone treatment in men with multiple sclerosis. NeuroImage Clinical. 2014;4:454–60. https://doi.org/10.1016/j.nicl.2014.03.001.CrossRefPubMedPubMedCentral

56.

Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–44. https://doi.org/10.1210/jc.2018-00229.CrossRefPubMed

57.

An KC. Selective estrogen receptor modulators. Asian Spine J. 2016;10(4):787–91. https://doi.org/10.4184/asj.2016.10.4.787.CrossRefPubMedPubMedCentral

58.

Solomon ZJ, Mirabal JR, Mazur DJ, Kohn TP, Lipshultz LI, Pastuszak AW. Selective androgen receptor modulators: current knowledge and clinical applications. Sex Med Rev. 2019;7(1):84–94. https://doi.org/10.1016/j.sxmr.2018.09.006.CrossRefPubMed

59.

Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol. 2007;18(Suppl 8):viii26-35. https://doi.org/10.1093/annonc/mdm263.CrossRefPubMed

60.

• Rankin KA, Mei F, Kim K, Shen YA, Mayoral SR, Desponts C, et al. Selective estrogen receptor modulators enhance CNS remyelination independent of estrogen receptors. J Neurosci. 2019;39(12):2184–94. https://doi.org/10.1523/jneurosci.1530-18.2019. (The authors validated the SERM bazedoxifene as a potent agent of OPC differentiation and remyelination.)CrossRefPubMedPubMedCentral

61.

Gonzalez GA, Hofer MP, Syed YA, Amaral AI, Rundle J, Rahman S, et al. Tamoxifen accelerates the repair of demyelinated lesions in the central nervous system. Sci Rep. 2016;6:31599. https://doi.org/10.1038/srep31599.CrossRefPubMedPubMedCentral

62.

Korade Z, Kim HY, Tallman KA, Liu W, Koczok K, Balogh I, et al. the effect of small molecules on sterol homeostasis: measuring 7-dehydrocholesterol in Dhcr7-deficient Neuro2a cells and human fibroblasts. J Med Chem. 2016;59(3):1102–15. https://doi.org/10.1021/acs.jmedchem.5b01696.CrossRefPubMedPubMedCentral

63.

Moebius FF, Reiter RJ, Bermoser K, Glossmann H, Cho SY, Paik YK. Pharmacological analysis of sterol delta8-delta7 isomerase proteins with [3H]ifenprodil. Mol Pharmacol. 1998;54(3):591–8. https://doi.org/10.1124/mol.54.3.591.CrossRefPubMed

64.

Gylling H, Pyrhonen S, Mantyla E, Maenpaa H, Kangas L, Miettinen TA. Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer. J Clin Oncol. 1995;13(12):2900–5. https://doi.org/10.1200/JCO.1995.13.12.2900.CrossRefPubMed

65.

• Kara F, Lohse CM, Castillo AM, Tosakulwong N, Lesnick TG, Jack CR Jr, et al. Association of raloxifene and tamoxifen therapy with cognitive performance, odds of mild cognitive impairment, and brain MRI markers of neurodegeneration. Cancer Med. 2023;12(3):2805–17. https://doi.org/10.1002/cam4.5175. (In this cross-sectional study, the authors found that use of tamoxifen or raloxifen was not associated with cognition in postmenopausal women.)CrossRefPubMed

66.

Underwood EA, Rochon PA, Moineddin R, Lee PE, Wu W, Pritchard KI, et al. Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis. Breast Cancer Res Treat. 2018;168(2):299–310. https://doi.org/10.1007/s10549-017-4627-4.CrossRefPubMed

67.

Liao KF, Lin CL, Lai SW. Nationwide case-control study examining the association between tamoxifen use and Alzheimer’s disease in aged women with breast cancer in Taiwan. Front Pharmacol. 2017;8:612. https://doi.org/10.3389/fphar.2017.00612.CrossRefPubMedPubMedCentral

68.

Branigan GL, Soto M, Neumayer L, Rodgers K, Brinton RD. association between hormone-modulating breast cancer therapies and incidence of neurodegenerative outcomes for women with breast cancer. JAMA Netw Open. 2020;3(3): e201541. https://doi.org/10.1001/jamanetworkopen.2020.1541.CrossRefPubMedPubMedCentral

69.

Mirkin S, Komm BS. Tissue-selective estrogen complexes for postmenopausal women. Maturitas. 2013;76(3):213–20. https://doi.org/10.1016/j.maturitas.2013.06.003.CrossRefPubMed

70.

Nylander A, Anderson A, Rowles W, Hsu S, Lazar AA, Mayoral SR, et al. Re-WRAP (Remyelination for women at risk of axonal loss and progression): a phase II randomized placebo-controlled delayed-start trial of Bazedoxifene for myelin repair in multiple sclerosis. Contemp Clin Trials. 2023;134: 107333. https://doi.org/10.1016/j.cct.2023.107333.CrossRefPubMed

71.

Akita K, Harada K, Ichihara J, Takata N, Takahashi Y, Saito K. A novel selective androgen receptor modulator, NEP28, is efficacious in muscle and brain without serious side effects on prostate. Eur J Pharmacol. 2013;720(1–3):107–14. https://doi.org/10.1016/j.ejphar.2013.10.042.CrossRefPubMed

72.

• Graham EL, Bakkensen JB, Anderson A, Lancki N, Davidson A, Perez Giraldo G, et al. Inflammatory activity after diverse fertility treatments: a multicenter analysis in the modern multiple sclerosis treatment era. Neurology(R) neuroimmunology & neuroinflammation. 2023;10(3). doi: https://doi.org/10.1212/nxi.0000000000200106. (In this multicenter observational study of patients with MS undergoing fertility treatments (FT), no elevated relapse risk after FT was observed.)

73.

Bove R, Rankin K, Lin C, Zhao C, Correale J, Hellwig K, et al. Effect of assisted reproductive technology on multiple sclerosis relapses: case series and meta-analysis. Mult Scler. 2020;26(11):1410–9. https://doi.org/10.1177/1352458519865118.CrossRefPubMed

74.

Mainguy M, Tillaut H, Degremont A, Le Page E, Mainguy C, Duros S, et al. Assessing the risk of relapse requiring corticosteroids after in vitro fertilization in women with multiple sclerosis. Neurology. 2022. https://doi.org/10.1212/wnl.0000000000201027.CrossRefPubMed

75.

Rosendale N, Ostendorf T, Evans DA, Weathers A, Sico JJ, Randall J, et al. American Academy of Neurology members’ preparedness to treat sexual and gender minorities. Neurology. 2019;93(4):159–66. https://doi.org/10.1212/wnl.0000000000007829.CrossRefPubMed

76.

Rosendale N, Wong JO, Flatt JD, Whitaker E. Sexual and gender minority health in neurology: a scoping review. JAMA Neurol. 2021;78(6):747–54. https://doi.org/10.1001/jamaneurol.2020.5536.CrossRefPubMedPubMedCentral

77.

Anderson A, Dierkhising J, Rush G, Carleton M, Rosendale N, Bove R. Experiences of sexual and gender minority people living with multiple sclerosis in Northern California: an exploratory study. Multiple sclerosis and related disorders. 2021;55: 103214. https://doi.org/10.1016/j.msard.2021.103214.CrossRefPubMed

78.

Khayambashi S, Salter A, Tyry T, Cutter GR, Fox RJ, Marrie RA. Gender identity and sexual orientation affect health care satisfaction, but not utilization, in persons with multiple sclerosis. Multiple sclerosis and related disorders. 2020;37: 101440. https://doi.org/10.1016/j.msard.2019.101440.CrossRefPubMed

79.

Lavorgna L, Moccia M, Russo A, Palladino R, Riccio L, Lanzillo R, et al. Health-care disparities stemming from sexual orientation of Italian patients with multiple sclerosis: a cross-sectional web-based study. Multiple Sclerosis Relat Disorders. 2017;13:28–32. https://doi.org/10.1016/j.msard.2017.02.001.CrossRef

80.

Sullivan A, Kane A, Valentic G, Rensel M. Recommendations to address the unique clinical and psychological needs of transgender persons living with multiple sclerosis. Int J MS Care. 2022;24(1):35–40. https://doi.org/10.7224/1537-2073.2021-066.CrossRefPubMedPubMedCentral

81.

Pakpoor J, Wotton CJ, Schmierer K, Giovannoni G, Goldacre MJ. Gender identity disorders and multiple sclerosis risk: a national record-linkage study. Mult Scler. 2016;22(13):1759–62. https://doi.org/10.1177/1352458515627205.CrossRefPubMed

82.

Campochiaro C, Host LV, Ong VH, Denton CP. Development of systemic sclerosis in transgender females: a case series and review of the literature. Clin Exp Rheumatol. 2018;36 Suppl 113(4):50–2.PubMed

83.

Hill BG, Hodge B, Misischia R. Lupus nephritis in a transgender woman on cross-sex hormone therapy: a case for the role of oestrogen in systemic lupus erythematosus. Lupus. 2020;29(13):1807–10. https://doi.org/10.1177/0961203320946372.CrossRefPubMed

84.

Pontes LT, Camilo DT, De Bortoli MR, Santos RSS, Luchi WM. New-onset lupus nephritis after male-to-female sex reassignment surgery. Lupus. 2018;27(13):2166–9. https://doi.org/10.1177/0961203318800571.CrossRefPubMed

85.

Salgado E, Romera-Baurés M, Beltran-Catalan E, Naredo E, Carreira PE, Garcia-Vivar M, et al. Inmune-mediated inflammatory rheumatic diseases in transgender people: a scoping review. Semin Arthritis Rheum. 2022;52: 151920. https://doi.org/10.1016/j.semarthrit.2021.10.004.CrossRefPubMed

86.

Santos-Ocampo AS. New onset systemic lupus erythematosus in a transgender man: possible role of feminizing sex hormones. J Clin Rheumatol. 2007;13(1):29–30. https://doi.org/10.1097/01.rhu.0000256169.05087.ad.CrossRefPubMed

87.

Connelly PJ, Marie Freel E, Perry C, Ewan J, Touyz RM, Currie G, et al. Gender-affirming hormone therapy, vascular health and cardiovascular disease in transgender adults. Hypertension. 2019;74(6):1266–74. https://doi.org/10.1161/hypertensionaha.119.13080.CrossRefPubMed

88.

LaHue SC, Torres D, Rosendale N, Singh V. Stroke characteristics, risk factors, and outcomes in transgender adults: a case series. Neurologist. 2019;24(2):66–70. https://doi.org/10.1097/nrl.0000000000000226.CrossRefPubMed

89.

Patel KT, Adeel S, Rodrigues Miragaya J, Tangpricha V. progestogen use in gender-affirming hormone therapy: a systematic review. Endocr Pract. 2022;28(12):1244–52. https://doi.org/10.1016/j.eprac.2022.08.012.CrossRefPubMed

Title: Hormonal Therapies in Multiple Sclerosis: a Review of Clinical Data
Authors: Stephanie Hsu
Riley Bove
Publication date: 16-12-2023
Publisher: Springer US
Keywords: Multiple Sclerosis
Endocrinology
Oral Contraception
Hormonal Replacement Therapy
Androgens
Fertility
Drug Therapy in Gender Medicine
Selective Estrogen Receptor Modulator
Estriol
Estrogens
Published in: Current Neurology and Neuroscience Reports / Issue 1/2024
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-023-01326-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hormonal Therapies in Multiple Sclerosis: a Review of Clinical Data

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content